Related Experiment Video
Updated: Oct 15, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Quantifying Renin-Angiotensin-System Alterations in COVID-19
Fabrizio Pucci1,2, Filippo Annoni3, Robson Augusto Souza Dos Santos4
13BIO-Computational Biology and Bioinformatics, Université Libre de Bruxelles, 1050 Brussels, Belgium.
Abstract:
The renin-angiotensin system (RAS) plays a pivotal role in a wide series of physiological processes, among which inflammation and blood pressure regulation. One of its key components, the angiotensin-converting enzyme 2, has been identified as the entry point of the SARS-CoV-2 virus into the host cells, and therefore a lot of research has been devoted to study RAS dysregulation in COVID-19. Here we discuss the alterations of the regulatory RAS axes due to SARS-CoV-2 infection on the basis of a series of recent clinical investigations and experimental analyzes quantifying, e.g., the levels and activity of RAS components. We performed a comprehensive meta-analysis of these data in view of disentangling the links between the impaired RAS functioning and the pathophysiological characteristics of COVID-19. We also review the effects of several RAS-targeting drugs and how they could potentially help restore the normal RAS functionality and minimize the COVID-19 severity. Finally, we discuss the conflicting evidence found in the literature and the open questions on RAS dysregulation in SARS-CoV-2 infection whose resolution would improve our understanding of COVID-19.
Insights
The renin-angiotensin system (RAS) is altered in COVID-19, impacting inflammation and blood pressure. Research explores RAS drug therapies to mitigate disease severity and understand infection mechanisms.
Area of Science:
- Physiology
- Virology
- Immunology
Background:
- The renin-angiotensin system (RAS) regulates critical physiological functions, including inflammation and blood pressure.
- Angiotensin-converting enzyme 2 (ACE2) is identified as the SARS-CoV-2 entry receptor, linking RAS to COVID-19 pathogenesis.
- SARS-CoV-2 infection causes significant dysregulation of the RAS, prompting extensive research.
Purpose of the Study:
- To analyze alterations in RAS regulatory axes caused by SARS-CoV-2 infection.
- To investigate the link between impaired RAS functioning and COVID-19 pathophysiology through meta-analysis.
- To review potential therapeutic strategies involving RAS-targeting drugs for COVID-19.
Main Methods:
- Comprehensive meta-analysis of clinical investigations and experimental data on RAS components in COVID-19.
- Quantification of RAS component levels and activity.
- Review of existing literature on RAS-targeting drugs and their effects.
Main Results:
- SARS-CoV-2 infection leads to significant alterations in RAS regulatory axes.
- Meta-analysis reveals links between impaired RAS functioning and COVID-19 characteristics.
- Evidence suggests potential benefits of RAS-targeting drugs in managing COVID-19 severity.
Conclusions:
- Understanding RAS dysregulation in COVID-19 is crucial for developing effective treatments.
- Further research is needed to resolve conflicting evidence and clarify open questions regarding RAS in SARS-CoV-2 infection.
- Targeting the RAS may offer a therapeutic avenue to restore normal function and reduce COVID-19 severity.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hormonal Regulation
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension II: Pathophysiology
Hypertension and Regulation of Blood Pressure

